METABOLIC TREATMENT WITH L-CARNITINE IN ACUTE ANTERIOR ST SEGMENT ELEVATION MYOCARDIAL INFARCTION: A RANDOMISED CONTROLLED TRIAL

Administration of L-carnitine in patients with anterior acute myocardial infarction (AMI) prevents left ventricular remodelling. Current study was aimed to assess the effect of L-carnitine administration on mortality and heart failure in patients with anterior AMI. CEDIM 2 trial was a randomized, double-blind, multicentre, placebo-controlled trial planned to enrol 4,000 patients with acute anterior AMI. The trial was interrupted after the enrolment of 2,330 patients because of the lower than expected enrolment rate. The primary end point was a composite of death and heart failure at 6 months; 5-day mortality was the secondary end point. During the 6-month follow-up, the primary endpoint was not significantly different between the L-carnitine and placebo group (9,2 vs. 10,5%, p=0,27). A reduction in mortality was seen in the L-carnitine arm on day 5 (secondary end-point) from randomization (HR=0,61, 95% CI 0,37–0,98, p=0,041). In CEDIM 2 trial L-carnitine therapy led to a reduction in early mortality (secondary end-point) without affecting the risk of death and heart failure at 6 months in patients with anterior AMI, leading to a non-significant finding with respect to the primary end-point.

1. Armstrong PW, Collen D: Fibrinolysis for acute myocardial infarction. Current status and new horizons for pharmacological reperfusion.Part I. Circulation 2001; 103; 2862-2866.

2. Armstrong PW, Collen D: Fibrinolysis for acute myocardial infarction. Current status and new horizons for pharmacological reperfusion. Part II. Circulation 2001; 103; 2987-2992.

3. Topol EJ: Current status and future prospects for acute myocardial infarction therapy. Circulation 2003; 108(suppl 1): III6–III13.

4. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML: Acute myocardial infarction. Lancet 2003; 361: 847–858.

5. Opie LH: Proof that glucose-insulin-potassium provides metabolic protection of ischemic myocardium? Lancet 1999; 353: 768–769.

6. Apstein CS: Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury. Am Heart J 2000; 139: S107–S114.

7. Fath-Ordoubadi F, Beatt KJ: Glucose-insulinpotassium therapy for treatment of acute myocardial infarction. Circulation 1997; 96: 1152–1156.

8. Van der Horst IC, Zijlstra F, van’t Hof AWJ, Doggen CJ, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrik JHE, Gans RJB, Bilo HJG; and Zwolle Infarct Study Group: Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003; 42: 784–791.

9. Opie LH: Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J 1979; 97: 375–388.

10. Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F: Myocardial carnitine defi ciency in acute myocardial infarction. Lancet 1982; 1: 1419–1420.

11. Fujiwara M, Nakano T, Tamato S, Yamada Y, Fukai M, Takada K, Ashida H, Shimada T, Ishihara T, Seki I: Effects of L -carnitine in patients with ischemic heart disease. Am J Cardiol 1991; 21: 493–504.

12. Lopaschuk G: Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 2000; 139: S115–S119.

13. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W: Infl uence of L -carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 2001; 51: 21–29.

14. С остальными литературными источниками (14-29) можно ознакомиться – cardio.nauka@yandex.ru